News

  • Oct 15, 2017

    Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague (Read more)

  • Sep 25, 2017

    Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland (Read more)

  • Sep 24, 2017

    Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th

  • Jul 3, 2017

    Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand

  • Jun 25, 2017

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

  • Mar 29, 2017

    Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain (Read more)

  • Mar 13, 2017

    Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France (Read more)

  • Dec 6, 2016

    Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea (Read more)

  • Nov 16, 2016

    Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Australia and New Zealand (Read more)

  • Nov 2, 2016

    Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (“PedPRM”) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD) (Read more)

  • Oct 5, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Honduras

  • Sep 28, 2016

    Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION – phase II clinical trial of Piromelatine for mild Alzheimer’s disease (Read more)

  • Aug 2, 2016

    Circadin® receives marketing authorization in Honduras

  • Jun 21, 2016

    Circadin® is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders (Read more)

  • Mar 3, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Peru

  • Mar 2, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

  • Jan 11, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in South Africa

  • Oct 1, 2015

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Colombia

  • Sep 18, 2015

    Circadin® receives marketing authorization in Peru

  • Mar 2, 2015

    Vigisom® 2mg (prolonged-release melatonin) is now commercially available in Chile

  • Text size: A A A
  • Circadin
  • Recent news

    • Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague
    • Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland
    • Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th
  • Partners

    Partners